Catalyst - Winter 2013 - IPO Window Wide Open as Biotech Stocks Sizzle!
In thinking about the 2013 biotech IPO whirlwind… what should people really be thinking now?
Work in biotech? Are you familiar with the public markets? Heck, ever heard of the FDA? You already know that the life sciences IPO marketplace is more than just "hot." As IPO lawyer Andy Gilbert of DLA Piper says: "It's crankin.'"
But you know all that. You waited patiently. Finally, in 2013, after an IPO drought -- no new opportunities to publicly invest in promising drugs, life-saving therapies and miraculous medical devices -- the flood gates flew open.
A year ago, it would have been difficult, and maybe even sad, to put together a "Top 10" year-to-date list of biotech IPOs (there were only 11). As of Nov. 1, 2013, a whopping 39 biotech companies hit the public markets to an incredible reception raising capital in numbers – a total of $3 billion to date.
The big question, or questions, on everyone's mind (sometimes just thought about but never uttered – Murphy's Law and all…) are "When will the biotech IPO window close," or – for those glass-half-full types, "How long will the window stay open?"
No one knows. Period.
However, Catalyst wanted to know what people do know about the current market – beyond the obvious. So, with that in mind, we approached several industry thought leaders and said: "Tell me something we don't know."
EisnerAmper's Catalyst: Winter 2013
- Welcome! One Size Doesn't Fit All - Corporate Finance for Life Science Companies
- 'Strong Story' Leads Niche Biotech Intercept to IPO Success
- IPO Window Wide Open as Biotech Stocks Sizzle!
- Tips from the Financial and Legal Gurus - Readying for an IPO? Make Sure to Get All Your Ducks in a Row!
- Weighing All the Options
- PTC's IPO Breaks Initial Records